Michel L Belley

This inventor holds 26 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Frosst Canada, Inc., Kaneq Pharma Inc., Merck Frosst Canada & Co.. Active years: 1988-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michel L Belley. Retrieved from https://idiyas.com/inventor/michel-l-belley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 96.2

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.7

ph-index = 10

Forward Citations = 384(Granted Patents)

Location History:

St. Laurent, CA (1988 - 1999)
Pierrefonds, CA (1993 - 2016)

Company Filing History:

18 out of 212

Merck Frosst Canada, Inc.

Merck Frosst Canada & Co.

Years Active: 1988-2016

Loading Chart...

Areas of Expertise:

PTP-1B Inhibitors

COX-2 Inhibitors

Leukotriene Antagonists

Quinoline Derivatives

Aromatic Compounds

Anti-inflammatory Drugs

Prostaglandin Receptor Ligands

Chiral Thioacetals

Pharmaceutical Compositions

Heteroaryl Compounds

Saturated Hydroxyalkylquinoline

Diarylstylquinoline Diacids

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9334295 - Fused aromatic PTP-1B inhibitors (2016-05-10),

2. 8927526 - Fused aromatic PTP-1B inhibitors (2015-01-06),

3. 8481742 - Fused aromatic PTP-1B inhibitors (2013-07-09),

4. 8168815 - Fused aromatic PTP-1B inhibitors (2012-05-01),

5. 8013159 - Quinoline derivatives as EP4 antagonists (2011-09-06),

6. 6242493 - Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment (2001-06-05),

7. 6211197 - Prostaglandin receptor ligands (2001-04-03),

8. 6169188 - (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors (2001-01-02),

9. 6020343 - (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors (2000-02-01),

10. 5981576 - (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors (1999-11-09),

11. 5856322 - Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists (1999-01-05),

12. 5565473 - Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists (1996-10-15),

13. 5510368 - N-benzyl-3-indoleacetic acids as antiinflammatory drugs (1996-04-23),

14. 5438141 - Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid (1995-08-01),

15. 5428033 - Saturated hydroxyalkylquinoline acids as leukotriene antagonists (1995-06-27),

Title: The Innovative Contributions of Michel L. Belley

Introduction

Michel L. Belley, located in St. Laurent, Canada, is a prolific inventor known for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 26 patents, his work primarily focuses on developing innovative compounds that address critical health challenges, particularly those related to enzyme inhibition.

Latest Patents

Among his latest innovations, Michel has developed compounds termed "Fused Aromatic PTP-1B Inhibitors." This invention represents a novel class of compounds designed to inhibit the PTP-1B enzyme. The implications of this invention are profound, as it also includes pharmaceutical compositions that incorporate these compounds, offering methods for treating or preventing diseases mediated by PTP-1B, including diabetes.

Career Highlights

Michel has a distinguished career, having worked with prominent companies in the pharmaceutical industry, including Merck Frosst Canada, Inc. and Kaneq Pharma Inc. His expertise and relentless pursuit of innovation have positioned him as a crucial figure in the development of new therapeutic agents.

Collaborations

Throughout his career, Michel has collaborated with esteemed colleagues such as Serge Leger and Patrick Roy. These partnerships have fostered an environment of creativity and innovation, significantly enhancing the impact of their collective work in the biotechnology landscape.

Conclusion

Michel L. Belley's contributions to pharmaceutical innovation through his extensive patent portfolio exemplify his commitment to advancing medical science. His latest work on PTP-1B inhibitors not only showcases his inventive spirit but also promises to pave the way for new treatments in diabetes and other related diseases. As he continues his work, the implications of his inventions are expected to resonate within the medical community for years to come.

Profile summary based on public USPTO records.